# NEONATAL Medication Monograph

## PENTOXIFYLLINE

*(For Nebulisation)*

This document should be read in conjunction with this **DISCLAIMER**

**Restricted:** Requires Neonatologist review within 24 hours of initiation

**SAS Category A** (item requires approval by TGA)

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Ampoule (SAS): 100mg/5mL = 20mg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Vasodilator - May reduce blood viscosity and improve blood flow by altering the rheology of red blood cells. Inhibits neutrophil activation and adhesion and platelet aggregation</td>
</tr>
</tbody>
</table>
| Indications  | • Treatment of peripheral and cerebral vascular disorders.  
• Rescue medication for chronic lung disease |
| Precautions  | Caution use in patients at risk of bleeding |
| Dosage       | **For Nebulisation ONLY** |
|              | Duration of therapy = 10 days |
|              | **Neonate Spontaneously Breathing**  
20 mg/ kg/ dose every 6 hours |
|              | **Intubated Neonate**  
10 mg/ kg/ dose every 6 hours |
|              | *If required, the 10 day course may be repeated after an interval of 5 days* |
| Adverse Reactions | **Common:** flushes, pruritus, urticaria, GI effects (nausea, vomiting, diarrhoea)  
**Serious:** anaphylaxis, cardiac arrhythmias, intrahepatic cholestasis, transaminase elevation |
| Preparation  | Prepared in Pharmacy  
If unavailable – use undiluted: Concentration = 20mg/mL |
Administration

Administer undiluted via Nebulisation until no fluid remains.

**Note:** The expiratory block of ventilators should be changed on a weekly basis when nebulised drugs are used.

Monitoring

Oxygen saturation

Storage

Store at room temperature, below 25°C

Notes

Must not be used in patients with increased risk of bleeding

SAS approval must be obtained for use of this medication

References


